TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14628428

Group type: EXPERIMENTAL
Intervention: 5FU/Lev (50 mg orally three times/day for 3 days, repeated every 2 weeks for 1 year)
Number of subjects: 185

Group type: COMPARATOR
Intervention: 5FU alone (450 mg/m2 i.v. bolus daily for 5 days and then weekly for 48 weeks)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 5FU/Lev and 5FU alone
Number of subjects: 185
Study: 11104315

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment for anxious ADHD children
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medication response
Number of subjects: 100
Study: 9347433

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 81
Study: 8247036

Group type: EXPERIMENTAL
Intervention: Higher doses of cisplatin (100 mg/m²) and cyclophosphamide (300 mg/m²)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Lower doses of cisplatin (80 mg/m²) and cyclophosphamide (225 mg/m²)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Higher doses of cisplatin and cyclophosphamide
Number of subjects: 105

Group type: COMPARATOR
Intervention: Lower doses of cisplatin and cyclophosphamide
Number of subjects: 105
Study: 3440987

Group type: EXPERIMENTAL
Intervention: Weight reduction programme supervised by dietitians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-dieting obese hypertensive patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight reduction programme for obese normotensive patients
Number of subjects: 0
Study: 30420969

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus Oral Hypoglycemic Agents (OHAs)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Insulin glargine plus OHAs
Number of subjects: 68
Study: 29944308

Group type: EXPERIMENTAL
Intervention: Monthly Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Daily Proguanil
Number of subjects: 154
Study: 23872937

Group type: EXPERIMENTAL
Intervention: Ball skill intervention (practiced in relative static, simple settings and more dynamic and cognitive demanding settings)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (received the school's regular physical education lessons)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ball skill intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 22763796

Group type: EXPERIMENTAL
Intervention: Immediate SWL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed SWL
Number of subjects: 0
Study: 20097076

Group type: EXPERIMENTAL
Intervention: Body weight support at 0%, 20%, 40%, 60%, 100% with stride frequency at 0.40, 0.49, 0.57 Hz
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High levels of body weight support and faster stride frequencies
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower levels of body weight support and slower stride frequency
Number of subjects: 8
Study: 18539666

Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone acetonide, bupivacaine, and epinephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Injection mixture without triamcinolone (Control)
Number of subjects: 90
Study: 16921006

Group type: EXPERIMENTAL
Intervention: Person-centered training with showering for 6 weeks (Time 1)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Person-centered training with towel bath for 6 weeks (Time 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Person-centered training (both interventions)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual showering procedures without person-centered training
Number of subjects: 69
Study: 12676261

Group type: EXPERIMENTAL
Intervention: Amifostine 500 mg i.v. prior to each radiotherapy fraction
Number of subjects: 54

Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 54
Study: 11077135

Group type: EXPERIMENTAL
Intervention: L-arginine (6 g/24 h for 3 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 25
Study: 8915139

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% applied topically after UVB irradiation (300 and 320 nm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% applied topically after UVA2 irradiation (330 and 340 nm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% applied topically after UVA1 irradiation (350 and 370 nm)
Number of subjects: 0
Study: 1348663

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 275 mg (two capsules)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (two identical capsules)
Number of subjects: 44
Study: 6140355

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic women who later acquired other endocrine disease
Number of subjects: 95

Group type: COMPARATOR
Intervention: Insulin-dependent diabetic women without other endocrine disease
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: First pregnancy of women with other endocrine disease
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Second pregnancy of women with other endocrine disease
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Third pregnancy of women with other endocrine disease
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fourth pregnancy of women with other endocrine disease
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Offspring of women with other endocrine disease
Number of subjects: 95

Group type: COMPARATOR
Intervention: Offspring of other diabetic mothers
Number of subjects: 95
Study: 31356450

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) plus treatment-as-usual (TAU)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: FibroQoL plus TAU
Number of subjects: 225

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 225
Study: 29373393

Group type: EXPERIMENTAL
Intervention: Extended-Release Naltrexone (XR-NTX)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 27312514

Group type: EXPERIMENTAL
Intervention: pemetrexed-cisplatin
Number of subjects: 97

Group type: COMPARATOR
Intervention: etoposide-cisplatin
Number of subjects: 97
Study: 25417609

Group type: EXPERIMENTAL
Intervention: Standard enteral product added to regulated hospital diets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Regulated hospital diets only
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (Study and Control)
Number of subjects: 38
Study: 22529301

Group type: EXPERIMENTAL
Intervention: ALVAC‐HIV (vCP1521) and AIDSVAX B/E vaccine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 20598985

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Combination of Valsartan and Captopril
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control group (other causes of death)
Number of subjects: 589
Study: 18222373

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7.5%) resuscitation with or without dextran
Number of subjects: 5848

Group type: COMPARATOR
Intervention: Conventional isotonic resuscitation
Number of subjects: 5848
Study: 16001651

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 12427399

Group type: EXPERIMENTAL
Intervention: Intranasal estradiol 300 microg/day (one spray delivery of 150 microg per nostril)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oral estradiol 2 mg/day
Number of subjects: 201
Study: 10518632

Group type: EXPERIMENTAL
Intervention: Individual Bioequivalence (IBE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population Bioequivalence (PBE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scaling methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broadening BE limits
Number of subjects: 0
Study: 7723351

Group type: EXPERIMENTAL
Intervention: Buflomedil 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buflomedil 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buflomedil 200 mg
Number of subjects: 10
Study: 2032104

Group type: EXPERIMENTAL
Intervention: Anal endosonography
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Electromyography
Number of subjects: 13
Study: 7034161

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone (Triolandren, 348 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testosterone propionate injections (84 mg every other day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peroral testosterone administration (800 mg micronized free testosterone daily)
Number of subjects: 24
Study: 31909912

Group type: EXPERIMENTAL
Intervention: Blended training (2 hours of virtual training and 2 hours of in-person instruction)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard training (4 hours of standard instruction from a trainer)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (Blended and Standard)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Blended training and Standard training
Number of subjects: 89
Study: 31455936

Group type: EXPERIMENTAL
Intervention: Eye health education via various methods (radio, television)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Radio for health education in Doti
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Television for health education in Saptari
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Dependence on drug retailers, self-medication, and traditional healers
Number of subjects: 15000
Study: 28315891

Group type: EXPERIMENTAL
Intervention: Rice/lentil RUCF
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Chickpea RUCF
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Plumpy'doz
Number of subjects: 5000

Group type: COMPARATOR
Intervention: WSB++
Number of subjects: 5000
Study: 25912336

Group type: EXPERIMENTAL
Intervention: 100-PCMSsingle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100-PCMSspaced
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50-PCMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50-TMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall MEPs
Number of subjects: 10
Study: 24487701

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) over supplementary motor area
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 19
Study: 22776019

Group type: EXPERIMENTAL
Intervention: Prednisolone plus placebo (n = 210)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Valaciclovir plus placebo (n = 207)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Prednisolone plus valaciclovir (n = 206)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo plus placebo (n = 206)
Number of subjects: 829
Study: 19487942

Group type: EXPERIMENTAL
Intervention: Educational program focusing on hand hygiene and catheter care
Number of subjects: 999
Study: 17520791

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 21
Study: 15126538

Group type: EXPERIMENTAL
Intervention: Metformin and resistance training three times a week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 25
Study: 11590477

Group type: EXPERIMENTAL
Intervention: Endurance groups (R, TA, CJ, CP)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: DHS
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: S
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All endurance disciplines
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 94

Group type: COMPARATOR
Intervention: UT
Number of subjects: 94

Group type: COMPARATOR
Intervention: LS
Number of subjects: 94
Study: 9855386

Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diet and aerobic training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diet and strength training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 45
Study: 7857455

Group type: EXPERIMENTAL
Intervention: Fetal movement counting
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Sleep recording
Number of subjects: 613

Group type: COMPARATOR
Intervention: Nonrecording control group
Number of subjects: 613
Study: 2792461

Group type: EXPERIMENTAL
Intervention: 1 alpha‐OHD group (0.75 micrograms of 1 alpha‐OHD and 400 mg of calcium daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Thiazide group (1 alpha‐OHD, calcium and 4 mg of trichlormethiazide)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment for osteoporosis)
Number of subjects: 38
Study: 800385

Group type: EXPERIMENTAL
Intervention: 0.05% diflorasone diacetate cream
Number of subjects: 384

Group type: COMPARATOR
Intervention: 0.05% fluocinonide cream
Number of subjects: 384
Study: 30047785

Group type: EXPERIMENTAL
Intervention: eHealth behaviour change intervention
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: self-allocated stage outcomes
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: social-cognitive variables
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: stage measures validity
Number of subjects: 310
Study: 28916537

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study: 25575977

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SRS/SRT
Number of subjects: 35
Study: 22926233

Group type: EXPERIMENTAL
Intervention: Zileuton ER 2400 mg/d
Number of subjects: 210

Group type: COMPARATOR
Intervention: Montelukast 10 mg/d
Number of subjects: 210
Study: 20974066

Group type: EXPERIMENTAL
Intervention: Acceptability E-scale
Number of subjects: 627
Study: 19522258

Group type: EXPERIMENTAL
Intervention: Music therapy (M group, n=29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (C group, n=29)
Number of subjects: 58
Study: 17466593

Group type: EXPERIMENTAL
Intervention: Intensified Training (IT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal Training (NT)
Number of subjects: 16
Study: 15191153

Group type: EXPERIMENTAL
Intervention: Lidocaine intradermal injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Saline intradermal injection (Control)
Number of subjects: 68
Study: 11703413

Group type: EXPERIMENTAL
Intervention: PA‐IgG against GP V (ratio > or = 1.5)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Degree of PA‐IgG measured by PIFT
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GP V‐specific antibodies
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GP V‐specific PA‐IgG
Number of subjects: 69
Study: 9497188

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 7868978

Group type: COMPARATOR
Intervention: Dietary cholesterol 0 mg (no fat, no cholesterol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol 140 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol 280 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol 710 mg
Number of subjects: 10
Study: 3283987

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 114

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 114
Study: 29306945

Group type: EXPERIMENTAL
Intervention: Weekly semistandardized e‐mail feedback from psychologists (individual counseling)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Automated, standardized feedback where a psychologist could be contacted on demand (CoD)
Number of subjects: 1089
Study: 27874934

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation combined with inhalational NO therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: High-frequency oscillatory ventilation
Number of subjects: 86
Study: 24700467

Group type: COMPARATOR
Intervention: Continuous wave CO2 laser (5 W)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pulsed CO2 laser (140 Hz, 400 microseconds, 33 mJ, 4.62 W)
Number of subjects: 100
Study: 22458660

Group type: EXPERIMENTAL
Intervention: Interferential current (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 41
Study: 20004661

Group type: EXPERIMENTAL
Intervention: 0.5 mg farglitazar
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 1.0 mg farglitazar
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 18407452

Group type: EXPERIMENTAL
Intervention: ACUSEAL (Gore-Tex) patching
Number of subjects: 200

Group type: COMPARATOR
Intervention: Finesse (Hemashield) patching
Number of subjects: 200
Study: 16159938

Group type: EXPERIMENTAL
Intervention: Cosyntropin 1.0 microg/kg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Cosyntropin 0.1 microg/kg
Number of subjects: 276
Study: 12677095

Group type: EXPERIMENTAL
Intervention: Drug-free hydrophilic microemulsion (ME)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Drug-free lipophilic microemulsion (ME)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% salicylic acid gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study: 14728001

Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb/IIIa inhibitors
Number of subjects: 42000
Study: 9034269

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: IL-1beta (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neutrophil pretreatment with inotropes
Number of subjects: 6
Study: 8290675

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 3554943

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29706170

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Alcohol Education (AE)
Number of subjects: 228
Study: 27121724

Group type: EXPERIMENTAL
Intervention: 5‐2‐1‐0 intervention program
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8
Study: 25695061

Group type: COMPARATOR
Intervention: Dexamethasone (8 mg before induction of anesthesia)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subhypnotic propofol (1 mg/kg/h during operation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (10% intralipid infusion)
Number of subjects: 120
Study: 23879477

Group type: EXPERIMENTAL
Intervention: Diode laser enucleation of the prostate (DiLEP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plasmakinetic enucleation and resection of the prostate (PKERP)
Number of subjects: 80
Study: 20621711

Group type: EXPERIMENTAL
Intervention: Lamotrigine (400 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 120
Study: 17692949

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation during surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 52
Study: 16803840

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cryoablation (CA)
Number of subjects: 71
Study: 14709929

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11056241

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) as a daily oral dose of estradiol, 2 mg, and norethisterone acetate, 1 mg, plus monthly subcutaneous implants of goserelin acetate for up to 2 years.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Monthly subcutaneous implants of goserelin acetate for up to 2 years without HRT.
Number of subjects: 49
Study: 8822684

Group type: EXPERIMENTAL
Intervention: Clonidine patch delivering 0.2mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31240553

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (physician, pharmacist, and nurse)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 143
Study: 30137193

Group type: EXPERIMENTAL
Intervention: Lefitolimod maintenance therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Local standard of care
Number of subjects: 103
Study: 27437913

Group type: EXPERIMENTAL
Intervention: L-thyroxine for 3-6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normal thyroid function)
Number of subjects: 32
Study: 25323094

Group type: EXPERIMENTAL
Intervention: CSCCM Instructional Module (2-h didactic session, 8-h preclinical session, 8-h clinical session, 1-h Q&A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 26
Study: 22375570

Group type: EXPERIMENTAL
Intervention: PATHS program (90‐minute, small‐group, participatory workshop with 6 months of structured telephone support)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 211
Study: 18275866

Group type: EXPERIMENTAL
Intervention: Injection duration of 25 s
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection duration of 30 s
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection duration of 35 s
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection duration of 40 s
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection duration of 45 s
Number of subjects: 75